Collaborative international clinical trials testing full dose anticoagulation with heparin (a blood thinner) in both moderately ill and critically ill patients has found the treatment improves outcomes and reduces the need for vital organ support such as mechanical ventilation in moderately ill patients. Thetrials found heparin does not yield the same positive outcomes among critically ill patients already requiring life support, according to two international studies published on 4 August 2021 in the prestigiousNew England Journal of Medicine (see links below).

Senior author on the studies, Ryan Zarychanski, MD, MSc, Associate Professor of Internal Medicine at University of Manitoba and hematologist, critical care physician and senior scientist at CancerCare Manitoba, Canada, said: "We had an unprecedented opportunity to work with colleagues across Canada, US and around the world to test the benefit of full-dose blood thinners on hospitalized Covid-19 patients. Therapeutic heparin improved survival and decreased progression to severe disease, thus reducing the pressure on intensive care units globally."

Lo studio multicentrico è stato coordinato dal San Raffaele Roma.

Un vasto studio multicentrico italiano condotto su pazienti emicranici cronici con almeno 5 tentativi terapeutici pregressi falliti ha verificato che l’uso prolungato di un anticorpo monoclonale riduce di almeno il 50% i giorni di emicrania nel 75,6% dei casi. Per oltre il 44% dei soggetti coinvolti nella ricerca si arriva addirittura a una riduzione pari o superiore al 75%. Si tratta del primo studio al mondo real-life a lungo termine con anticorpi monoclonali anti-CGRP nell’emicrania, coordinato dall’IRCCS San Raffaele Roma e pubblicato dalla prestigiosa rivista americana Headache: “Long-term effectiveness, safety, and tolerability of eremunab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study”.